U-47700

U-47700 is a synthetic opioid substance of the benzamide chemical class that produces analgesic, relaxing, sedative, and euphoric effects when administered. It was first developed by a team at Upjohn in the 1970s and is structurally related to earlier opioid drugs such as spiradoline and U-50488.

History

U-47700 was first synthesized in the mid-1970s by a team at Upjohn, a pharmaceutical company. It was part of a series of opioids developed by the company in the 1970s and 1980s, including U-50488 and U-69,593. These drugs were developed as potential analgesics or painkillers, but none of them were ever marketed.

Pharmacology

U-47700 acts as a mu-opioid receptor agonist. It is selective for the μ-opioid receptor and has a high binding affinity for it. This is the same mechanism of action as other opioids, and it is responsible for the drug's analgesic and euphoric effects.

Effects

The effects of U-47700 are similar to those of other opioids. They include analgesia, a sense of relaxation, and euphoria. However, the drug also has a number of adverse effects, including respiratory depression, constipation, itching, and addiction. Overdose can lead to fatal respiratory depression.

Legal status

U-47700 is a controlled substance in many countries, including the United States, where it is a Schedule I drug under the Controlled Substances Act. It is also controlled under similar laws in other countries, including the United Kingdom, Canada, and Australia.

See also

• List of opioids
• Opioid epidemic
• Designer drug

U-47700 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia